Abeona therapeutics announces presentation at the association for research in vision and ophthalmology (arvo) annual meeting

New york and cleveland, april 29, 2022 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in cell and gene therapy, today announced that preclinical data on aav204, a novel adeno-associated virus (aav) capsid from abeona's in-licensed aim™ capsid library, will be presented at the association for research and vision in ophthalmology (arvo) annual meeting, to be held on may 1-4, 2022 in denver, co and virtually on may 11-12, 2022.
ABEO Ratings Summary
ABEO Quant Ranking